World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
122
Citations
86894
World Ranking
3400
National Ranking
1871

Research.com Recognitions

  • 2018 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Patrick Hwu is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the fields of Medicine, Immunology and Microbiology, and Biochemistry, Genetics and Molecular Biology.

The scientist's work largely focuses on topics related to Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, and Immunotherapy and Immune Responses. Additional topics include Cancer Genomics and Diagnostics, Immune Cell Function and Interaction, Ocular Oncology and Treatments, and Colorectal Cancer Treatments and Studies.

Frequent coauthors with whom Patrick Hwu has collaborated include Sapna P. Patel, Michael A. Davies, Adi Diab, Chantale Bernatchez, and Cara Haymaker.

They have published extensively in several venues, with multiple papers appearing in the following journals and conference collections:

  • Journal for ImmunoTherapy of Cancer
  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Nature Communications
  • Journal of Clinical Oncology

Selected recent papers highlight the scope of their research:

  • "Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study" (2020), Journal of Clinical Oncology
  • "Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)" (2020), Cancer Discovery
  • "Immuno-genomic landscape of osteosarcoma" (2020), Nature Communications
  • "Comprehensive T cell repertoire characterization of non-small cell lung cancer" (2020), Nature Communications
  • "Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial" (2022), The Lancet Oncology

Patrick Hwu's subfields of study further include Oncology, Immunology, Molecular Biology, Cancer Research, and Ophthalmology.

In recognition of their contributions to science, Patrick Hwu was named a Fellow of the American Association for the Advancement of Science (AAAS) in 2018.

Best Publications

  • Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

    Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu

  • Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

    V. Gopalakrishnan;V. Gopalakrishnan;C. N. Spencer;C. N. Spencer;L. Nezi;A. Reuben

  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

    Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  • A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

    James C. Yang;Leah Haworth;Richard M. Sherry;Patrick Hwu

  • B cells and tertiary lymphoid structures promote immunotherapy response

    Beth A. Helmink;Sangeetha M. Reddy;Jianjun Gao;Shaojun Zhang

  • Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

    Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  • Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

    Sattva S. Neelapu;Sudhakar Tummala;Partow Kebriaei;William Wierda

  • Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

    Giao Q. Phan;James C. Yang;Richard M. Sherry;Patrick Hwu

  • Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

    Weiyi Peng;Jie Qing Chen;Chengwen Liu;Shruti Malu

  • A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

    Michael H. Kershaw;Michael H. Kershaw;Michael H. Kershaw;Jennifer A. Westwood;Jennifer A. Westwood;Linda L. Parker;Gang Wang;Gang Wang

  • PD-L1 Expression in Triple-Negative Breast Cancer

    Elizabeth A Mittendorf;Anne V Philips;Funda Meric-Bernstam;Na Qiao

  • A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

    Livnat Jerby-Arnon;Parin Shah;Michael S. Cuoco;Christopher Rodman

  • Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

    Jianjun Gao;Lewis Zhichang Shi;Hao Zhao;Jianfeng Chen

  • gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

    Douglas J. Schwartzentruber;David H. Lawson;Jon M. Richards;Robert M. Conry

  • BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma

    Dennie Tompers Frederick;Adriano Piris;Alexandria P. Cogdill;Zachary A. Cooper

  • Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer

    James C. Yang;Richard M. Sherry;Seth M. Steinberg;Suzanne L. Topalian

  • Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

    Pei Ling Chen;Whijae Roh;Alexandre Reuben;Zachary A. Cooper

  • T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity

    Natalia Martin-Orozco;Pawel Muranski;Yeonseok Chung;Xuexian O. Yang

  • INDOLEAMINE 2,3-DIOXYGENASE PRODUCTION BY HUMAN DENDRITIC CELLS RESULTS IN THE INHIBITION OF T CELL PROLIFERATION

    Patrick Hwu;Mark X. Du;Réjean Lapointe;My Do

  • Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6

    Katsutoshi Ozaki;Katsutoshi Ozaki;Rosanne Spolski;Rachel Ettinger;Hyoung Fyo Kim

Frequent Co-Authors

Michael A. Davies
Michael A. Davies The University of Texas MD Anderson Cancer Center
Chantale Bernatchez
Chantale Bernatchez The University of Texas MD Anderson Cancer Center
Adi Diab
Adi Diab The University of Texas MD Anderson Cancer Center
Laszlo Radvanyi
Laszlo Radvanyi Ontario Institute for Cancer Research
Cara Haymaker
Cara Haymaker The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo
Jennifer A. Wargo The University of Texas MD Anderson Cancer Center
Willem W. Overwijk
Willem W. Overwijk The University of Texas MD Anderson Cancer Center
Alexander J. Lazar
Alexander J. Lazar The University of Texas MD Anderson Cancer Center
Jason Roszik
Jason Roszik The University of Texas MD Anderson Cancer Center
Jeffrey E. Gershenwald
Jeffrey E. Gershenwald The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in Medicine, several flexible online pathways can help fast-track your career or enable specialization. For registered nurses seeking advancement without extensive on-site training, there are rn to bsn programs no clinicals that offer a convenient, fully online option. These programs allow you to earn a BSN without the need for additional clinical hours.

Nurses aiming for leadership roles can explore the shortest msn to dnp program, which accelerates the journey from master’s to doctorate. For those prioritizing accessibility and work-life balance, the easiest dnp program online offers a more manageable approach to earning your DNP.

Entry-level roles are also available for those new to healthcare. You might consider fast track medical lpn options. These programs are designed to help you qualify as a Licensed Practical Nurse more quickly, offering a stepping stone into the nursing field.

Each of these online pathways supports diverse career goals, making it easier than ever to advance in the dynamic medical field.

Best Scientists Citing Patrick Hwu

Trending Scientists